1 Joshi, S. S. & Badgwell, B. D. Current treatment and recent progress in gastric cancer. CA Cancer J Clin 71, 264-279, doi:10.3322/caac.21657 (2021).
2 Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71, 209-249, doi:10.3322/caac.21660 (2021).
3 Sharma, A. et al. Hypoxia-targeted drug delivery. Chem Soc Rev 48, 771-813, doi:10.1039/c8cs00304a (2019).
4 Patel, A. & Sant, S. Hypoxic tumor microenvironment: Opportunities to develop targeted therapies. Biotechnol Adv 34, 803-812, doi:10.1016/j.biotechadv.2016.04.005 (2016).
5 Hammond, E. M. & Giaccia, A. J. Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers? Clinical cancer research : an official journal of the American Association for Cancer Research 12, 5007-5009, doi:10.1158/1078-0432.CCR-06-0613 (2006).
6 Ohtsu, A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29, 3968-3976, doi:10.1200/JCO.2011.36.2236 (2011).
7 Yoon, H. H. et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol 27, 2196-2203, doi:10.1093/annonc/mdw423 (2016).
8 Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31-39, doi:10.1016/S0140-6736(13)61719-5 (2014).
9 Nowak, R. P. et al. Advances and challenges in understanding histone demethylase biology. Curr Opin Chem Biol 33, 151-159, doi:10.1016/j.cbpa.2016.06.021 (2016).
10 Hojfeldt, J. W., Agger, K. & Helin, K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 12, 917-930, doi:10.1038/nrd4154 (2013).
11 Kooistra, S. M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13, 297-311, doi:10.1038/nrm3327 (2012).
12 Xhabija, B. & Kidder, B. L. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer. Seminars in cancer biology 57, 79-85, doi:10.1016/j.semcancer.2018.11.001 (2019).
13 Yu, X. et al. Chromatin remodeling: demethylating H3K4me3 of type I IFNs gene by Rbp2 through interacting with Piasy for transcriptional attenuation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 32, 552-567, doi:10.1096/fj.201700088RR (2018).
14 Xu, J. et al. Metabolic enzyme PDK3 forms a positive feedback loop with transcription factor HSF1 to drive chemoresistance. Theranostics 9, 2999-3013, doi:10.7150/thno.31301 (2019).
15 Zhou, Q. et al. Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells. JCI Insight 4, doi:10.1172/jci.insight.121582 (2019).
16 Barysch, S. V., Dittner, C., Flotho, A., Becker, J. & Melchior, F. Identification and analysis of endogenous SUMO1 and SUMO2/3 targets in mammalian cells and tissues using monoclonal antibodies. Nat Protoc 9, 896-909, doi:10.1038/nprot.2014.053 (2014).
17 Harris, A. L. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38-47, doi:10.1038/nrc704 (2002).
18 Buuh, Z. Y., Lyu, Z. & Wang, R. E. Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins. J Med Chem 61, 3239-3252, doi:10.1021/acs.jmedchem.6b01817 (2018).
19 Kim, Y. S., Keyser, S. G. & Schneekloth, J. S., Jr. Synthesis of 2',3',4'-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation. Bioorg Med Chem Lett 24, 1094-1097, doi:10.1016/j.bmcl.2014.01.010 (2014).
20 Langston, S. P. et al. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. J Med Chem 64, 2501-2520, doi:10.1021/acs.jmedchem.0c01491 (2021).
21 Yuan, H. et al. Small ubiquitin-related modifier paralogs are indispensable but functionally redundant during early development of zebrafish. Cell Res 20, 185-196, doi:10.1038/cr.2009.101 (2010).
22 Rabellino, A., Andreani, C. & Scaglioni, P. P. The Role of PIAS SUMO E3-Ligases in Cancer. Cancer research 77, 1542-1547, doi:10.1158/0008-5472.CAN-16-2958 (2017).
23 Xu, W. et al. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. International journal of biological sciences 14, 1122-1132, doi:10.7150/ijbs.25881 (2018).
24 Hendriks, I. A. et al. Site-specific characterization of endogenous SUMOylation across species and organs. Nature communications 9, 2456, doi:10.1038/s41467-018-04957-4 (2018).
25 Cai, Q., Verma, S. C., Kumar, P., Ma, M. & Robertson, E. S. Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PloS one 5, e9720, doi:10.1371/journal.pone.0009720 (2010).
26 Chien, W. et al. PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. Br J Cancer 109, 1795-1804, doi:10.1038/bjc.2013.531 (2013).
27 Xu, R. et al. Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. Onco Targets Ther 6, 925-929, doi:10.2147/OTT.S46487 (2013).
28 Eder, J. P., Jr. et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20, 3772-3784, doi:10.1200/JCO.2002.02.082 (2002).
29 Wouters, B. G. & Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8, 851-864, doi:10.1038/nrc2501 (2008).
30 Batie, M. et al. Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science 363, 1222-1226, doi:10.1126/science.aau5870 (2019).
31 Chakraborty, A. A. et al. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science 363, 1217-1222, doi:10.1126/science.aaw1026 (2019).
32 Thienpont, B. et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537, 63-68, doi:10.1038/nature19081 (2016).
33 Kim, Y. et al. Methylation-dependent regulation of HIF-1alpha stability restricts retinal and tumour angiogenesis. Nature communications 7, 10347, doi:10.1038/ncomms10347 (2016).
34 Lee, J. Y. et al. LSD1 demethylates HIF1alpha to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis. Oncogene 36, 5512-5521, doi:10.1038/onc.2017.158 (2017).
35 Wilson, V. G. Introduction to Sumoylation. Adv Exp Med Biol 963, 1-12, doi:10.1007/978-3-319-50044-7_1 (2017).
36 Li, J. et al. Cbx4 governs HIF-1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer cell 25, 118-131, doi:10.1016/j.ccr.2013.12.008 (2014).
37 Carbia-Nagashima, A. et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131, 309-323, doi:10.1016/j.cell.2007.07.044 (2007).
38 Cheng, J., Kang, X., Zhang, S. & Yeh, E. T. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131, 584-595, doi:10.1016/j.cell.2007.08.045 (2007).
39 Desterro, J. M., Rodriguez, M. S. & Hay, R. T. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Molecular cell 2, 233-239, doi:10.1016/s1097-2765(00)80133-1 (1998).
40 Guzzo, C. M. et al. RNF4-dependent hybrid SUMO-ubiquitin chains are signals for RAP80 and thereby mediate the recruitment of BRCA1 to sites of DNA damage. Sci Signal 5, ra88, doi:10.1126/scisignal.2003485 (2012).
41 Raimondi, A. et al. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. Pharmacogenomics 19, 1047-1068, doi:10.2217/pgs-2018-0077 (2018).
42 Fu, Y. D. et al. Targeting histone demethylase KDM5B for cancer treatment. Eur J Med Chem 208, 112760, doi:10.1016/j.ejmech.2020.112760 (2020).
43 Zheng, Y. C. et al. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target. Eur J Med Chem 161, 131-140, doi:10.1016/j.ejmech.2018.10.040 (2019).
44 Sachdev, S. et al. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes & development 15, 3088-3103, doi:10.1101/gad.944801 (2001).
45 Gross, M., Yang, R., Top, I., Gasper, C. & Shuai, K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 23, 3059-3066, doi:10.1038/sj.onc.1207443 (2004).
oi:
10.1200/JCO.2011.36.2236.
Yoon HH, et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016;27:2196–203. doi:10.1093/annonc/mdw423. Fuchs CS, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9. doi:10.1016/S0140-6736(13)61719-5. Nowak RP, et al. Advances and challenges in understanding histone demethylase biology. Curr Opin Chem Biol. 2016;33:151–9. doi:10.1016/j.cbpa.2016.06.021. Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov. 2013;12:917–30. doi:10.1038/nrd4154. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012;13:297–311. doi:10.1038/nrm3327. Xhabija B, Kidder BL. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer. Sem Cancer Biol. 2019;57:79–85. doi:10.1016/j.semcancer.2018.11.001. Yu X, et al. Chromatin remodeling: demethylating H3K4me3 of type I IFNs gene by Rbp2 through interacting with Piasy for transcriptional attenuation. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2018;32:552–67. doi:10.1096/fj.201700088RR. Xu J, et al. Metabolic enzyme PDK3 forms a positive feedback loop with transcription factor HSF1 to drive chemoresistance. Theranostics. 2019;9:2999–3013. doi:10.7150/thno.31301. Zhou Q, et al. Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells. JCI Insight 4, doi:10.1172/jci.insight.121582 (2019). Barysch SV, Dittner C, Flotho A, Becker J, Melchior F. Identification and analysis of endogenous SUMO1 and SUMO2/3 targets in mammalian cells and tissues using monoclonal antibodies. Nat Protoc. 2014;9:896–909. doi:10.1038/nprot.2014.053. Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47. doi:10.1038/nrc704. Buuh ZY, Lyu Z, Wang RE. Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins. J Med Chem. 2018;61:3239–52. doi:10.1021/acs.jmedchem.6b01817. Kim YS, Keyser SG, Schneekloth JS. Jr. Synthesis of 2',3',4'-trihydroxyflavone (2-D08), an inhibitor of protein sumoylation. Bioorg Med Chem Lett. 2014;24:1094–7. doi:10.1016/j.bmcl.2014.01.010. Langston SP, et al. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. J Med Chem. 2021;64:2501–20. doi:10.1021/acs.jmedchem.0c01491. Yuan H, et al. Small ubiquitin-related modifier paralogs are indispensable but functionally redundant during early development of zebrafish. Cell Res. 2010;20:185–96. doi:10.1038/cr.2009.101. Rabellino A, Andreani C, Scaglioni PP. The Role of PIAS SUMO E3-Ligases in Cancer. Cancer research. 2017;77:1542–7. doi:10.1158/0008-5472.CAN-16-2958. Xu W, et al. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. Int J Biol Sci. 2018;14:1122–32. doi:10.7150/ijbs.25881. Hendriks IA, et al. Site-specific characterization of endogenous SUMOylation across species and organs. Nature communications. 2018;9:2456. doi:10.1038/s41467-018-04957-4. Cai Q, Verma SC, Kumar P, Ma M, Robertson ES. Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PloS one. 2010;5:e9720. doi:10.1371/journal.pone.0009720. Chien W, et al. PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. Br J Cancer. 2013;109:1795–804. doi:10.1038/bjc.2013.531. Xu R, et al. Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. Onco Targets Ther. 2013;6:925–9. doi:10.2147/OTT.S46487. Eder JP Jr, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002;20:3772–84. doi:10.1200/JCO.2002.02.082. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851–64. doi:10.1038/nrc2501. Batie M, et al. Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science. 2019;363:1222–6. doi:10.1126/science.aau5870. Chakraborty AA, et al. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science. 2019;363:1217–22. doi:10.1126/science.aaw1026. Thienpont B, et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature. 2016;537:63–8. doi:10.1038/nature19081. Kim Y, et al. Methylation-dependent regulation of HIF-1alpha stability restricts retinal and tumour angiogenesis. Nature communications. 2016;7:10347. doi:10.1038/ncomms10347. Lee JY, et al. LSD1 demethylates HIF1alpha to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis. Oncogene. 2017;36:5512–21. doi:10.1038/onc.2017.158. Wilson VG. Introduction to Sumoylation. Adv Exp Med Biol. 2017;963:1–12. doi:10.1007/978-3-319-50044-7_1. Li J, et al. Cbx4 governs HIF-1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer cell. 2014;25:118–31. doi:10.1016/j.ccr.2013.12.008. Carbia-Nagashima A, et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell. 2007;131:309–23. doi:10.1016/j.cell.2007.07.044. Cheng J, Kang X, Zhang S, Yeh ET. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell. 2007;131:584–95. doi:10.1016/j.cell.2007.08.045. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Molecular cell. 1998;2:233–9. doi:10.1016/s1097-2765(00)80133-1. Guzzo CM, et al. RNF4-dependent hybrid SUMO-ubiquitin chains are signals for RAP80 and thereby mediate the recruitment of BRCA1 to sites of DNA damage. Sci Signal. 2012;5:ra88. doi:10.1126/scisignal.2003485. Raimondi A, et al. Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. Pharmacogenomics. 2018;19:1047–68. doi:10.2217/pgs-2018-0077. Fu YD, et al. Targeting histone demethylase KDM5B for cancer treatment. Eur J Med Chem. 2020;208:112760. doi:10.1016/j.ejmech.2020.112760. Zheng YC, et al. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target. Eur J Med Chem. 2019;161:131–40. doi:10.1016/j.ejmech.2018.10.040. Sachdev S, et al. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes Dev. 2001;15:3088–103. doi:10.1101/gad.944801. Gross M, Yang R, Top I, Gasper C, Shuai K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene. 2004;23:3059–66. doi:10.1038/sj.onc.1207443.